News

Feb. 17. 2025

Sawai Receives Approvals for a Single Generic Drug with One Strength

Dec. 05. 2024

Sawai Announces Listing of Five Generic Drugs with 10 Strengths

Aug. 16. 2024

Sawai Receives Approvals for Six Generic Drugs with 11 Strengths

Jun. 13. 2024

Sawai Announces Listing of Two Generic Drugs with Three Strengths

Feb. 15. 2024

Sawai Receives Approvals for Three Generic Drugs with Four Strengths

Dec. 07. 2023

Sawai Announces Listing of a single Generic Drug with Two Strengths

Nov. 07. 2023

Launch of Pitavastatin tablets in the United States – Sawai’s First generic ANDA approval and launch for US market under Paragraph IV–

Jun. 15. 2023

Sawai Announces Listing of Two Generic Drugs with Eight Strengths

Feb. 15. 2023

Sawai Receives Approvals for Three Generic Drugs with 10 Strengths

Dec. 27. 2022

Sawai Pharmaceutical Applies for Marketing and Manufacturing Approval for Non-Invasive Neuromodulation Device

Dec. 08. 2022

Sawai Announces Listing of Six Generic Drugs with 12 Strengths

Aug. 16. 2022

Sawai Receives Approvals for Six Generic Drugs with 13 Strengths

Jun. 16. 2022

Sawai Announces Listing of Five Generic Drugs with 11 Strengths

Feb. 15. 2022

Sawai Receives Approvals for Seven Generic Drugs with 14 Strengths

Dec. 09. 2021

Sawai Announces Listing of Five Generic Drugs with Nine Strengths

Dec. 03. 2021

Sawai Group Holdings and ORIX Agree on Conclusion of Transfer Agreement with Kobayashi Kako -Toward Early Establishment of In-house Annual Production Capacity of 20 Billion Tablets or More-

Aug. 16. 2021

Sawai Receives Approvals for Four Generic Drugs with Eight Strengths

Jun. 17. 2021

Sawai Launches Eight Generic Drugs with 23 Strengths

Apr. 01. 2021

Notice of Establishment of Sawai Group Holdings

Feb. 15. 2021

Sawai Receives Approvals for Eight Generic Drugs with 20 Strengths

Feb. 12. 2021

Sawai Reports Third Quarter FY2020 Financial Results

Dec. 16. 2020

Upsher-Smith Launches Ramelteon Tablets

Dec. 10. 2020

Sawai Launches Two Generic Drugs with 10 Strengths

Nov. 24. 2020

Notice of Convocation of an Extraordinary General Meeting of Shareholders and the Matters to be Resolved Thereat, as well as Partial Amendments to the Articles of Incorporation